Risks and benefits of erythropoiesis-stimulating agents in cancer management.

abstract：:Autologous hematopoietic stem cell transplantation (HSCT) has a long tradition in Europe. Initially developed as a tool to restore rapid remission or chronic phase in patients with advanced leukemia without a sibling donor, it evolved over the last three decades to be used as a standard tool in patients with malignanc...

journal_title：Seminars in hematology

authors： Gratwohl A

更新日期：2007-10-01 00:00:00

abstract：:A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

journal_title：Seminars in hematology

authors： Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

更新日期：2001-04-01 00:00:00

abstract：:The virome has been recently studied in hematology and mostly in the setting of allogeneic hematopoietic stem cell transplantation. However, in hematology (as in the setting of nonhematological disorders) the study of the microbiome (that indeed includes the virome) is a growing field. The overall field is moving beyo...

journal_title：Seminars in hematology

authors： Legoff J,Michonneau D,Socie G

更新日期：2020-01-01 00:00:00

abstract：:Despite the development of more effective therapies for multiple myeloma (MM) over the past decade, nearly all patients will eventually experience disease relapse and require further therapy. Designing the next generation of therapies for relapsed and refractory disease will depend on understanding the complex molecul...

journal_title：Seminars in hematology

authors： Siegel DS

更新日期：2012-07-01 00:00:00

abstract：:Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

journal_title：Seminars in hematology

authors： Gangat N,Wolanskyj AP

更新日期：2013-07-01 00:00:00

abstract：:Two membrane proteins express the antigens that comprise the Kell blood group system. A single antigen, Kx, is carried on XK, a 440-amino acid protein that spans the membrane 10 times, and more than 20 antigens reside on Kell, a 93-kd, type II glycoprotein. XK and Kell are linked, close to the membrane surface, by a s...

journal_title：Seminars in hematology

authors： Lee S,Russo D,Redman CM

更新日期：2000-04-01 00:00:00

abstract：:Because optimal management of iron chelation therapy in patients with sickle cell disease and transfusional iron overload requires accurate determination of the magnitude of iron excess, a variety of techniques for evaluating iron overload are under development, including measurement of serum ferritin iron levels, x-r...

journal_title：Seminars in hematology

authors： Brittenham GM,Sheth S,Allen CJ,Farrell DE

更新日期：2001-01-01 00:00:00

abstract：:Iron is a vitally important element in mammalian metabolism because of its unsurpassed versatility as a biologic catalyst. However, when not appropriately shielded or when present in excess, iron plays a key role in the formation of extremely toxic oxygen radicals, which ultimately cause peroxidative damage to vital c...

journal_title：Seminars in hematology

authors： Ponka P

更新日期：2002-10-01 00:00:00

abstract：:The successful clinical development of thalidomide, bortezomib, and lenalidomide not only transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a renewed interest in the development of additional classes of novel agents for this disease. This review focuses on a series of new therapeutics ...

journal_title：Seminars in hematology

authors： Mitsiades CS,Hideshima T,Chauhan D,McMillin DW,Klippel S,Laubach JP,Munshi NC,Anderson KC,Richardson PG

更新日期：2009-04-01 00:00:00

abstract：:While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL. Moreover, the burden of therapy is high in a significant number of newly di...

journal_title：Seminars in hematology

authors： Jeha S

更新日期：2009-01-01 00:00:00

abstract：:It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For many years immunosuppression with antilymphocyte antibodies has been a standard treatment approach for patients with severe aplastic anemia (SAA). The ...

journal_title：Seminars in hematology

authors： Parikh AR,Olnes MJ,Barrett AJ

更新日期：2012-10-01 00:00:00

abstract：:High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for th...

journal_title：Seminars in hematology

authors： Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

更新日期：2002-01-01 00:00:00

abstract：:Smoldering myeloma (SMM) is a precursor state of multiple myeloma. It is defined by an M-protein concentration ≥3 g/dL and/or ≥10% clonal bone marrow plasma cells, in the absence of end-organ damage. Based on clinical observations, the natural history of SMM varies greatly, from stable, monoclonal gammopathy of undete...

journal_title：Seminars in hematology

authors： Landgren O,Rajkumar SV

更新日期：2011-01-01 00:00:00

abstract：:There is consensus that human herpesvirus 8 (HHV-8) is a necessary, albeit not sufficient, causal agent of Kaposi's sarcoma (KS). In the past several years, there have been rapid advances in our understanding of HHV-8 infection. In diagnosis, antibody detection is more sensitive than nucleic acid-based techniques. Whi...

journal_title：Seminars in hematology

authors： Martin JN

更新日期：2003-04-01 00:00:00

abstract：:The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

journal_title：Seminars in hematology

authors： Richardson P

更新日期：2005-10-01 00:00:00

abstract：:This report suggests modest changes in the criteria used for the diagnosis of ET and allows tentative recommendations concerning therapy. As outlined in Table I, we believe that absent stainable marrow iron does not necessarily indicate iron deficiency in these patients and that the serum ferritin and RBC mean corpusc...

journal_title：Seminars in hematology

authors： Murphy S,Peterson P,Iland H,Laszlo J

更新日期：1997-01-01 00:00:00

abstract：:Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

journal_title：Seminars in hematology

authors： Hoelzer D,Gökbuget N,Ottmann OG

更新日期：2002-10-01 00:00:00

abstract：:These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to ident...

journal_title：Seminars in hematology

authors： Koeffler HP

更新日期：1996-04-01 00:00:00

abstract：:The antiviral and antigrowth activity of interferon (IFN) makes this agent a promising approach to cancer therapy. Three tumors that are unusually sensitive to IFN-a are chronic myelogenous leukemia (CML) in the benign phase, hairy-cell leukemia, and the T-cell lymphomas associated with mycosis fungoides. Studies usin...

journal_title：Seminars in hematology

authors： Gutterman JU

更新日期：1988-07-01 00:00:00

abstract：:Activation products of the terminal complement cascade potently affect granulocyte function, inducing, for example, their migration toward (chemotaxis), and adherence to (opsonization), microbes, and stimulating their production of microbicidal oxygen radicals such as superoxide anion, and the like. We present studies...

journal_title：Seminars in hematology

authors： Craddock PR,Hammerschmidt DE,Moldow CF,Yamada O,Jacob HS

更新日期：1979-04-01 00:00:00

abstract：:Hereditary hemochromatosis is one of the most common inherited disorders among Caucasians of European ancestry. Malregulation of iron absorption from the duodenum eventually leads to iron overload. Although the time required to become iron loaded is variable, it is clear that most homozygotes will eventually become sy...

journal_title：Seminars in hematology

authors： Edwards CQ,Griffen LM,Ajioka RS,Kushner JP

更新日期：1998-01-01 00:00:00

abstract：:Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in vitro even prior to the first reports of clinical resistance in patients with chronic myeloid leukemia (CML). The discovery that BCR-ABL is reactivated at the time of resistance and the unveiling of point mutations within the ...

journal_title：Seminars in hematology

authors： La Rosée P,Deininger MW

更新日期：2010-10-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by malignant expansion of bone marrow stem cells. Currently, the only unequivocally curative treatment for CML is allogeneic stem cell transplant. Unfortunately, a large proportion of CML patients are ineligible for such treatment and alternative...

journal_title：Seminars in hematology

authors： Barnes DJ,Melo JV

更新日期：2003-01-01 00:00:00

abstract：:The activation, function, and development of peripheral T lymphocytes are dependent on the ability to signal properly through the surface T-cell antigen receptor (TCR)-CD3 complex. Transmission of such signals requires the activation of specific cytoplasmic protein tyrosine kinases (PTK) associated with the TCR. Recen...

journal_title：Seminars in hematology

authors： Elder ME

更新日期：1998-10-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesyl...

journal_title：Seminars in hematology

authors： Appelbaum FR

更新日期：2001-07-01 00:00:00

abstract：:Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk...

journal_title：Seminars in hematology

authors： Fuji S,Kapp M,Einsele H

更新日期：2012-01-01 00:00:00

abstract：:The purpose of this study was to assess the efficacy and side effect profile of the repeated use of anti-D for the treatment of pediatric immune thrombocytopenia (ITP) in a large pediatric hematology center. We performed a retrospective analysis of patient records for children (aged 4 months-18 years) treated for ITP ...

journal_title：Seminars in hematology

authors： Yacobovich J,Abu-Ahmed S,Steinberg-Shemer O,Goldberg T,Cohen M,Tamary H

更新日期：2016-04-01 00:00:00

abstract：:Imatinib (Gleevec) (formerly STI571) is an orally bioavailable rationally developed inhibitor of the tyrosine kinases Bcr-Abl, Kit, and platelet-derived growth factor receptor (PDGFR). In 4 years of clinical development, more than 12,000 patients have been treated in the clinical development program. Imatinib was firs...

journal_title：Seminars in hematology

authors： Capdeville R,Silberman S

更新日期：2003-04-01 00:00:00

abstract：:Our advanced knowledge of coagulation has led to the synthesis of novel procoagulant substances, such as recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark). Similarly, in-depth understanding of the interaction between anticoagulant proteins and their natural inhibitors has led to th...

journal_title：Seminars in hematology

authors： Ng HJ,Crowther MA

更新日期：2006-01-01 00:00:00

abstract：:Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian pop...

journal_title：Seminars in hematology

authors： Kongtim P,Ciurea SO

更新日期：2019-07-01 00:00:00